Current pharmacotherapy options for bulimia nervosa and binge eating disorder

Bibliography

• A.P.A. Diagnostic and statistical manual of mental disorders. 4th edition. Text Revision American Psychiatric Association; Washington, DC: 2000
   Google Scholar
• Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet 2010;375(9714):583-93
   PubMed Web of Science ®Google Scholar
• Wonderlich SA, Gordon KH, Mitchell JE, The validity and clinical utility of binge eating disorder. Int J Eat Disord 2009;42(8):687-705
   PubMed Web of Science ®Google Scholar
• A.P.A. DSM-5: feeding and Eating Disorders. Available from: http://www.dsm5.org/proposedrevision/Pages/FeedingandEatingDisorders.aspx [Last accesed 2012 July 5]
   Google Scholar
• Hudson JI, Hiripi E, Pope HG Jr, The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007;61(3):348-58
   PubMed Web of Science ®Google Scholar
• Swanson SA, Crow SJ, Le Grange D, Prevalence and correlates of eating disorders in adolescents: results from the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry 2011;68:714-23
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Crow SJ. Medical comorbidities of eating disorders. In: Agras WS, editor. The Oxford handbook of eating disorders. Oxford University Press; New York: 2010. p. 259
   Google Scholar
• Hudson JI, Lalonde JK, Coit CE, Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge eating disorder. Am J Clin Nutrition 2010;91(6):1568-73
   PubMed Web of Science ®Google Scholar
• Walsh BT, Boudreau G. Laboratory studies of binge eating disorder. Int J Eat Disord 2003;34(Suppl):S30-8
   PubMedGoogle Scholar
• Berner LA, Bocarsly ME, Hoebel BG, Pharmacological interventions for binge eating: lessons from animal models, current treatments, and future directions. Curr Pharm Des 2011;17(12):1180-7
   PubMed Web of Science ®Google Scholar
• Wang G-J, Geliebter A, Volkow ND, Enhanced striatal dopamine release during food stimulation in binge eating disorder. Obesity (Silver Spring) 2011;19:1601-8
   PubMed Web of Science ®Google Scholar
• Hay PP, Bacaltchuk J, Stefano S, Psychological treatments for bulimia nervosa and binging. Cochrane Database Syst Rev 2009(4):CD000562
   Google Scholar
• Wilson GT. Treatment of binge eating disorder. Psychiatr Clin North Am 2011;34(4):773-83
   PubMed Web of Science ®Google Scholar
• Yager J. Management of patients with chronic, intractable eating disorders. In: Yager J, Powers PS, editors. Clinical manual of eating disorders. American Psychiatric Publishin, Washington, DC; 2007. p. 407-39
   Google Scholar
• Berkman ND, Bulik CM, Brownley KA, Management of eating disorders. Evid Rep Technol Assess (Full Rep) 2006; Apr(135):1-166
   PubMedGoogle Scholar
• Hay PJ, Bacaltchuk J. Bulimia nervosa. Clin Evid (Online) 2008;2008:1009
   PubMedGoogle Scholar
• Reas DL, Grilo CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity (Silver Spring) 2008;16(9):2024-38
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova A, O'Melia AM, Pharmacotherapy of the eating disorders. In: Agras S, editor. Oxford Handbook of Eating Disorders. Oxford University Press, Inc; New York, NY: 2010. p. 417-51
   Google Scholar
• Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol 2012;15(2):189-207
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Mori N, Pharmacolgical management of binge eating disorder: current and emerging treatment options. Therapeutics and Clinical Risk Management 2012;8:219-41
   PubMed Web of Science ®Google Scholar
• NICE. Eating disorders. Core interventions in the treatment and managment of anorexia nervosa, bulimia nervosa and related eating disorders. Clinical guideline no 9. London January 2004
   Google Scholar
• A.P.A. Treatment of patients with eating disorders, third edition. American Psychiatric Association. Am J Psychiatry 2006;163(7 Suppl):4-54
   PubMed Web of Science ®Google Scholar
• Aigner M, Treasure J, Kaye W, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011;12(6):400-43
   PubMed Web of Science ®Google Scholar
• Bacaltchuk J, Hay PPJ. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003(4):CD003391
   Google Scholar
• Milano W, Petrella C, Sabatino C, Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther 2004;21(4):232-7
   PubMed Web of Science ®Google Scholar
• Milano W, Siano C, Putrella C, Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther 2005;22(3):278-83
   PubMed Web of Science ®Google Scholar
• Stefano SC, Bacaltchuk J, Blay SL, Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eat Behav 2008;9(2):129-36
   PubMedGoogle Scholar
• FBNCSG. Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-47
   PubMed Web of Science ®Google Scholar
• Walsh BT, Agras WS, Devlin MJ, Fluoxetine for bulimia nervosa following poor response to psychotherapy. Am J Psychiatry 2000;157(8):1332-4
   PubMed Web of Science ®Google Scholar
• Walsh BT, Fairburn CG, Mickley D, Treatment of bulimia nervosa in a primary care setting. Am J Psychiatry 2004;161(3):556-61
   PubMedGoogle Scholar
• Sysko R, Sha N, Wang Y, Early response to antidepressant treatment in bulimia nervosa. Psychol Med 2010;40(6):999-1005
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Wilson GT. Rapid response to treatment for binge eating disorder. J Consult Clin Psychol 2006;74(3):602-13
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Winstanley EL, Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial. Int J Eat Disord 2012;45:281-9
   PubMed Web of Science ®Google Scholar
• Horne RL, Ferguson JM, Pope HG Jr, Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988;49(7):262-6
   PubMed Web of Science ®Google Scholar
• Calandra C, Russo RG, Luca M. Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: Retrospective cohort study. Psychiatr Q 2011;83(2):177-85
   Google Scholar
• Fichter MM, Kruger R, Rief W, Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 1996;16(1):9-18
   PubMed Web of Science ®Google Scholar
• Romano SJ, Halmi KA, Sarkar NP, A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002;159(1):96-102
   PubMed Web of Science ®Google Scholar
• Leombruni P, Piero A, Lavagnino L, A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(6):1599-605
   PubMed Web of Science ®Google Scholar
• Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev 2001(4):CD003385
   Google Scholar
• Laederach-Hofmann K, Graf C, Horber F, Imipramine and diet counseling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord 1999;26(3):231-44
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison. Biol Psychiatry 2005;57(3):301-9
   PubMed Web of Science ®Google Scholar
• Devlin MJ, Goldfein JA, Petkova E, Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res 2005;13(6):1077-88
   PubMedGoogle Scholar
• Malhotra S, King KH, Welge JA, Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry 2002;63(9):802-6
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Martens B, Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009;23(2):139-56
   PubMedGoogle Scholar
• Kaplan AS, Garfinkel PE, Darby PL, Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983;140(9):1225-6
   PubMed Web of Science ®Google Scholar
• Hoopes SP, Reimherr FW, Hedges DW, Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003;64(11):1335-41
   PubMed Web of Science ®Google Scholar
• Hedges DW, Reimherr FW, Hoopes SP, Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003;64(12):1449-54
   PubMed Web of Science ®Google Scholar
• Nickel C, Tritt K, Muehlbacher M, Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord 2005;38(4):295-300
   PubMed Web of Science ®Google Scholar
• McElroy SL, Arnold LM, Shapira NA, Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003;160(2):255-61
   PubMed Web of Science ®Google Scholar
• McElroy SL, Hudson JI, Capece JA, Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry 2007;61(9):1039-48
   PubMed Web of Science ®Google Scholar
• Claudino AM, de Oliveira IR, Appolinario JC, Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry 2007;68(9):1324-32
   PubMed Web of Science ®Google Scholar
• Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61(5):368-72
   PubMed Web of Science ®Google Scholar
• Kotwal R, Guerdjikova A, McElroy SL, Lithium augmentation of topiramate for bipolar disorder with comorbid binge eating disorder and obesity. Hum Psychopharmacol 2006;21(7):425-31
   PubMedGoogle Scholar
• McElroy SL, Kotwal R, Guerdjikova AI, Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006;67(12):1897-906
   PubMed Web of Science ®Google Scholar
• Guerdjikova AI, McElroy SL, Welge JA, Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial. Int Clin Psychopharmacol 2009;24(3):150-8
   PubMed Web of Science ®Google Scholar
• Wermuth BM, Davis KL, Hollister LE, Phenytoin treatment of the binge-eating syndrome. Am J Psychiatry 1977;134(11):1249-53
   PubMed Web of Science ®Google Scholar
• McElroy SL, Shapira NA, Arnold LM, Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry 2004;65(11):1463-9
   PubMed Web of Science ®Google Scholar
• Ricca V, Castellini G, Lo Sauro C, Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study. Psychiatry (Edgmont) 2009;6(11):23-8
   PubMedGoogle Scholar
• Herridge PL, Pope HG, Jr. Treatment of bulimia and rapid-cycling bipolar disorder with sodium valproate: a case report. J Clin Psychopharmacol 1985;5(4):229-30
   PubMedGoogle Scholar
• Leombruni P, Gastaldi F, Lavagnino L, Oxcarbazepine for the treatment of binge eating disorder: a case series. Adv Ther 2008;25(7):718-24
   PubMedGoogle Scholar
• Stunkard A, Berkowitz R, Tanrikut C, D-fenfluramine treatment of binge eating disorder. Am J Psychiatry 1996;153(11):1455-9
   PubMed Web of Science ®Google Scholar
• Appolinario JC, Bacaltchuk J, Sichieri R, A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch Gen Psychiatry 2003;60(11):1109-16
   PubMed Web of Science ®Google Scholar
• Milano W, Petrella C, Casella A, Use of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled study. Adv Ther 2005;22(1):25-31
   PubMed Web of Science ®Google Scholar
• Wilfley DE, Crow SJ, Hudson JI, Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. Am J Psychiatry 2008;165(1):51-8
   PubMed Web of Science ®Google Scholar
• Grilo CM, Masheb RM, Salant SL. Cognitive behavioral therapy guided self-help and orlistat for the treatment of binge eating disorder: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2005;57(10):1193-201
   PubMed Web of Science ®Google Scholar
• Golay A, Laurent-Jaccard A, Habicht F, Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005;13(10):1701-8
   PubMedGoogle Scholar
• Fernandez-Aranda F, Amor A, Jimenez-Murcia S, Bulimia nervosa and misuse of orlistat: two case reports. Int J Eat Disord 2001;30(4):458-61
   PubMedGoogle Scholar
• Hagler Robinson A. Orlistat misuse as purging in a patient with binge-eating disorder. Psychosomatics 2009;50(2):177-8
   PubMedGoogle Scholar
• Aronne LJ, Halseth AE, Burns CM, Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity (Silver Spring) 2010;18(9):1739-46
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Powell AG, Apovian CM. Emerging pharmacotherapy for obesity. Expert Opin Emerg Drugs 2011;16(3):587-96
   PubMed Web of Science ®Google Scholar
• Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011;2011:179674
   PubMedGoogle Scholar
• Alger SA, Malone M, Cerulli J, Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. Obes Res 1999;7(5):469-76
   PubMedGoogle Scholar
• Devlin MJ, Goldfein JA, Carino JS, Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord 2000;28(3):325-32
   PubMedGoogle Scholar
• McElroy SL, Guerdjikova A, Kotwal R, Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry 2007;68(3):390-8
   PubMed Web of Science ®Google Scholar
• Ong YL, Checkley SA, Russell GF. Suppression of bulimic symptoms with methylamphetamine. Br J Psychiatry 1983;143:288-93
   PubMed Web of Science ®Google Scholar
• Shire. Shire Reports Positive Phase 2 Study Met Primary End Point for Investigative Use of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in Adults with Binge Eating Disorder. 2012. Available from: http://www.shire.com/shireplc/en/media/shirenews/?id=593 [Last accessed 14 June 2012]
   Google Scholar
• O'Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005;162(8):1423-31
   PubMed Web of Science ®Google Scholar
• Mitchell JE, Christenson G, Jennings J, A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 1989;9(2):94-7
   PubMed Web of Science ®Google Scholar
• Alger SA, Schwalberg MD, Bigaouette JM, Effect of a tricyclic antidepressant and opiate antagonist on binge-eating behavior in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 1991;53(4):865-71
   PubMed Web of Science ®Google Scholar
• Alkermes. Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder. 2011. Available from: http://investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=1582921&highlight [Last accessed 14 June 2012]
   Google Scholar
• Marrazzi MA, Bacon JP, Kinzie J, Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa. Int Clin Psychopharmacol 1995;10(3):163-72
   PubMed Web of Science ®Google Scholar
• Jonas JM, Gold MS. The use of opiate antagonists in treating bulimia: a study of low-dose versus high-dose naltrexone. Psychiatry Res 1988;24(2):195-9
   PubMed Web of Science ®Google Scholar
• Raingeard I, Courtet P, Renard E, Naltrexone improves blood glucose control in type 1 diabetic women with severe and chronic eating disorders. Diabetes Care 2004;27(3):847-8
   PubMedGoogle Scholar
• Marrazzi MA, Markham KM, Kinzie J, Binge eating disorder: response to naltrexone. Int J Obes Relat Metab Disord 1995;19(2):143-5
   PubMed Web of Science ®Google Scholar
• Neumeister A, Winkler A, Wober-Bingol C. Addition of naltrexone to fluoxetine in the treatment of binge eating disorder. Am J Psychiatry 1999;156(5):797
   PubMedGoogle Scholar
• Lightlake Therapeutics Inc. Lightlake Therapeutics Inc. Announces Positive Preliminary Phase II Clinical Trial Results of Binge Eating Disorder Treatment. 2012. Available from: http://www.prnewswire.com/news-releases/lightlake-therapeutics-inc-announces-positive-preliminary-phase-ii-clinical-trial-results-of-binge-eating-disorder-treatment-149993255.html [Last accessed 6 July 2012]
   Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376(9741):595-605
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Winstanley EL, Acamprosate in the treatment of binge eating disorder: a placebo-controlled trial. Int J Eat Disord 2011;44(1):81-90
   PubMed Web of Science ®Google Scholar
• Broft AI, Spanos A, Corwin RL, Baclofen for binge eating: an open-label trial. Int J Eat Disord 2007;40(8):687-91
   PubMed Web of Science ®Google Scholar
• Sundblad C, Landen M, Eriksson T, Effects of the androgen antagonist flutamide and the serotonin reuptake inhibitor citalopram in bulimia nervosa: a placebo-controlled pilot study. J Clin Psychopharmacol 2005;25(1):85-8
   PubMed Web of Science ®Google Scholar
• von Wietersheim J, Muler-Bock V, Rauh S, No effect of spironolactone on bulimia nervosa symptoms. J Clin Psychopharmacol 2008;28(2):258-60
   PubMedGoogle Scholar
• Faris PL, Kim SW, Meller WH, Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000;Mar4355(9206):792-7
   PubMed Web of Science ®Google Scholar
• FDA. FDA Drug Safety Communication: abnormal heart rhythms may be associated with use of Zofran (ondanestron). 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm [Last accessed 10 July 2012]
   Google Scholar
• Hsu LK, Clement L, Santhouse R, Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis 1991;179(6):351-5
   PubMed Web of Science ®Google Scholar
• Hermanussen M, Tresguerres JA. A new anti-obesity drug treatment: first clinical evidence that, antagonising glutamate-gated Ca2+ ion channels with memantine normalises binge-eating disorders. Econ Hum Biol 2005;3(2):329-37
   PubMed Web of Science ®Google Scholar
• Brennan BP, Roberts JL, Fogarty KV, Memantine in the treatment of binge eating disorder: an open-label, prospective trial. Int J Eat Disord 2008;41(6):520-6
   PubMed Web of Science ®Google Scholar
• McElroy SL, Guerdjikova AI, Winstanley EL, Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study. Int J Eat Disord 2011;44(3):262-8
   PubMed Web of Science ®Google Scholar
• Gebhardt S, Haberhausen M, Krieg JC, Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders. J Neural Transm 2007;114(8):1091-5
   PubMedGoogle Scholar
• Theisen FM, Linden A, Konig IR, Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003;110(1):111-21
   PubMed Web of Science ®Google Scholar
• Sysko R, Hildebrandt T, Wilson GT, Heterogeneity moderates treatment response among patients with binge eating disorder. J Consult Clin Psychol 2010;78(5):681-90
   PubMedGoogle Scholar
• Brambilla F, Samek L, Company M, Multivariate therapeutic approach to binge-eating disorder: combined nutritional, psychological and pharmacological treatment. Int Clin Psychopharmacol 2009;24(6):312-17
   PubMedGoogle Scholar
• Marilov VV, Sologub MB. Comparative effectiveness of mood stabilizers in the complex therapy of bulimia nervosa. Zh Nevrol Psikhiatr Im S S Korsakova 2010;110(1):59-61
   PubMedGoogle Scholar